All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

mosunetuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
monoclonal antibodies (humanized origin); tumor	5700	1905409-39-3

Description:

Molecule

Description

Molfile Synonyms: mosunetuzumab lunsumio RO7030816 RG7828 BTCT4465A

Mosunetuzumab is an anti-CD20/CD3 T-cell engaging bispecific antibody targeting CD20-expressing B-cells. It is a conditional agonist; targeted B-cell killing is observed only upon simultaneous binding to CD20 on B-cells and CD3 on T-cells. Engagement of both arms of mosunetuzumab results in the formation of an immunologic synapse between a target B cell and a cytotoxic T cell leading to T-cell activation. Subsequent directed release of perforin and granzymes from T-cell activation through the immunologic synapsis induce B-cell lysis leading to cell death. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
June 3, 2022	EMA	Roche Registration GmbH
Dec. 22, 2022	FDA	GENENTECH INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cytokine release syndrome	377.64	75.08	77	644	27896	90599830
Vasogenic cerebral oedema	178.26	75.08	26	695	1264	90626462
Disease progression	164.38	75.08	57	664	156558	90471168
Neurological symptom	134.90	75.08	26	695	6821	90620905
Diffuse large B-cell lymphoma recurrent	131.71	75.08	23	698	3503	90624223
Disorientation	86.75	75.08	26	695	44088	90583638
Therapy partial responder	84.81	75.08	22	699	22021	90605705

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cytokine release syndrome	215.65	58.14	57	432	44470	42576376
COVID-19	81.97	58.14	35	454	115913	42504933
COVID-19 pneumonia	64.05	58.14	19	470	21594	42599252

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cytokine release syndrome	517.21	60.04	126	1147	70180	110517846
Disease progression	182.96	60.04	77	1196	243957	110344069
Vasogenic cerebral oedema	153.90	60.04	26	1247	2232	110585794
COVID-19 pneumonia	124.52	60.04	36	1237	37107	110550919
Diffuse large B-cell lymphoma recurrent	109.75	60.04	23	1250	6276	110581750
Neurological symptom	103.79	60.04	26	1247	15582	110572444
Neutropenia	103.53	60.04	60	1213	374560	110213466
COVID-19	100.38	60.04	51	1222	245009	110343017
Malignant neoplasm progression	76.23	60.04	38	1235	174529	110413497
Disorientation	65.14	60.04	26	1247	70645	110517381
Therapy partial responder	61.42	60.04	21	1252	37040	110550986

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FX25	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates
MeSH PA	D000074322	Antineoplastic Agents, Immunological
MeSH PA	D000970	Antineoplastic Agents
CHEBI has role	CHEBI:35610	antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs

amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabdatopotamab deruxtecanelotuzumabelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Relapsed or refractory follicular lymphoma	indication	55150002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
B-lymphocyte antigen CD20	Surface antigen	P11836	CD20_HUMAN					UNKNOWN	DRUG LABEL

External reference:

ID	Source
CHEBI:757234	CHEBI
CHEMBL4297788	ChEMBL_ID
C000731929	MESH_SUPPLEMENTAL_RECORD_UI
12298	IUPHAR_LIGAND_ID
DB15434	DRUGBANK_ID
278181000202107	SNOMEDCT_US
4041943	VANDF
C4763385	UMLSCUI
10621	INN_ID
D11463	KEGG_DRUG
364475	MMSL
41159	MMSL
d09958	MMSL
019149	NDDF
LDJ89SS0YG	UNII
2625122	RXNORM

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lunsumio	HUMAN PRESCRIPTION DRUG LABEL	1	50242-142	CONCENTRATE	30 mg	INTRAVENOUS	BLA	31 sections
Lunsumio	HUMAN PRESCRIPTION DRUG LABEL	1	50242-159	CONCENTRATE	1 mg	INTRAVENOUS	BLA	31 sections
Lunsumio Velo	HUMAN PRESCRIPTION DRUG LABEL	1	50242-177	INJECTION	5 mg	SUBCUTANEOUS	BLA	30 sections
Lunsumio Velo	HUMAN PRESCRIPTION DRUG LABEL	1	50242-201	INJECTION	45 mg	SUBCUTANEOUS	BLA	30 sections